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Aims: Patients with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) exhibit consider-
able residual risk for cardiovascular disease (CVD). There is, therefore, increasing interest in targeting
postprandial lipid metabolism and remnant cholesterol. Treatment with the glucagon-like peptide
1 (GLP-1) analogue liraglutide reduces CVD risk by mechanisms that remain unexplained in part.
Here we investigated the effects of liraglutide intervention on ectopic fat depots, hepatic lipogene-
sis and fat oxidation, postprandial lipid metabolism and glycaemia in humans with type 2 diabetes.
Methods: The effect of liraglutide was investigated in 22 patients with adequately controlled
type 2 diabetes. Patients were randomly allocated, in a single-blind fashion, to either liraglutide
1.8 mg or placebo once daily for 16 weeks. Because liraglutide is known to promote weight loss,
the study included dietary counselling to achieve similar weight loss in the liraglutide and pla-
cebo groups. Cardiometabolic responses to a high-fat mixed meal were measured before and at
the end of the liraglutide intervention.
Results: Weight loss at Week 16 was similar between the groups: −2.4 kg (−2.5%) in the liraglutide
group and −2.1 kg (−2.2%) in the placebo group. HBA1c improved by 6.4 mmol/mol (0.6%) in the
liraglutide group (P = 0.005). Liver fat decreased in both groups, by 31% in the liraglutide group and
by 18% in the placebo group, but there were no significant changes in the rate of hepatic de novo
lipogenesis or β-hydroxybutyrate levels, a marker of fat oxidation. We observed significant post-
prandial decreases in triglycerides only in plasma, chylomicrons and VLDL, and remnant particle cho-
lesterol after treatment in the liraglutide group. Fasting and postprandial apoCIII concentrations
decreased after liraglutide intervention and these changes were closely related to reduced glycae-
mia. In relative importance analysis, approximately half of the changes in postprandial lipids were
explained by reductions in apoCIII concentrations, whereas less than 10% of the variation in post-
prandial lipids was explained by reductions in weight, glycaemic control, liver fat or postprandial
insulin responses.
Conclusions: Intervention with liraglutide for 16 weeks produces multiple improvements in car-
diometabolic risk factors that were not seen in the placebo group, despite similar weight loss.
Of particular importance was a marked reduction in postprandial atherogenic remnant particles.
The underlying mechanism may be improved glycaemic control, which leads to reduced expres-
sion of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
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1 | INTRODUCTION
It is well established that high plasma concentrations of cholesterol-
rich atherogenic lipoproteins are causatively linked to cardiovascular
disease (CVD).1 However, despite treatments that significantly lower
LDL concentrations, patients with type 2 diabetes and non-alcoholic
fatty-liver disease (NAFLD) retain a considerable residual risk of
CVD.2,3 There is, therefore, increasing interest in the role of plasma
triglycerides, a biomarker of circulating triglyceride-rich lipoproteins
(TRLs), and, in particular, their cholesterol-rich remnant particles, with
accumulating evidence that they are causatively linked to CVD.4,5 Of
note, the residual risk of CVD in patients with type 2 diabetes despite
treatment with statins may be explained, in part, by the fact that these
agents lower remnant cholesterol by only 4% to 25%, a point that is
not normally noted as remnant cholesterol is not quantified by routine
lipid measurements.6
Remnant lipoprotein particles are derived from the intestine (ie,
chylomicrons) and the liver (ie, VLDL).6 The plasma concentration of
these remnants is higher in patients with postprandial hypertriglyceri-
daemia, and non-fasting triglyceride levels have allowed prediction of
CVD risk more reliably than fasting triglyceride values.7 Although the
vast majority of plasma triglycerides after a fat-rich mixed meal come
from the intestine,8 approximately 80% of the increase in particle num-
ber is accounted for by remnant particles derived from VLDL metabo-
lism.9 Intestinal-derived chylomicron remnants and liver-derived VLDL
remnants are cleared from the circulation by common pathways and,
therefore, compete for clearance.10 Increased secretion of VLDL from
the liver is, therefore, an important predictor of postprandial accumula-
tion of chylomicron remnants.11 We have also demonstrated that
apoCIII is an important regulator of TRL remnant metabolism.12
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin
mimetics that safely and efficiently improve glycaemic control.13
Unlike other anti-diabetic agents, GLP-1 receptor agonists also pro-
mote significant weight reduction.13 Furthermore, these agents have
been reported to be cardioprotective,13,14 an important clinical benefit
given that CVD is the underlying cause of death in over 60% of
patients with type 2 diabetes. The exact mechanism underlying the
vascular benefit of GLP-1 receptor agonists remains debated. The
observed improvements in glycaemic control, weight loss and the
minor changes in fasting plasma lipids are not considered sufficient to
explain the robust benefits in CVD outcomes.14 However, animal and
clinical studies have demonstrated that incretin-based therapies
improve postprandial TRL metabolism.15–17
Interestingly, impaired incretin effects have been observed in
patients with NAFLD, both with and without diabetes.18,19 Conse-
quently, GLP-1 receptor agonists are increasingly recognized as potential
agents for treating NAFLD in patients with and without diabetes.20–22 It
is not clear, however, whether the actions of GLP-1 receptor agonists
are direct, through activation of GLP-1 receptors on hepatocytes,23 or
are related to their weight-loss properties.20 It is also unclear whether
the beneficial effects of GLP-1 receptor agonists on liver fat result from
decreased hepatic de novo lipogenesis or from increased hepatic fat
oxidation.
Here we investigated the effects of intervention with the GLP-1
analogue liraglutide for 16 weeks on glycaemia, ectopic fat depots,
hepatic lipogenesis and fat oxidation, and postprandial lipid metabolism
in humans with adequately controlled type 2 diabetes. The study was
designed to determine whether the cardiometabolic beneficial effects
of liraglutide are mainly weight independent or weight-loss dependent.
2 | METHODS
2.1 | Study design
The study was designed as a single-blinded, double-armed, single-centre
study at Helsinki University (Clinical Trials NCT02765399). Participants
were recruited through newspaper advertisements and websites making
the public aware of open clinical studies for individuals with diabetes.
The study protocol was approved by the ethics committee of Helsinki
University and Helsinki University Hospital (May 19, 2014; decision
number 31/13/01/01/2014) and the National Agency of Medicines,
Helsinki, Finland (April 8, 2014; EudraCT 2013-005075-40). The study
participants were enrolled between February 2015 and November
2017. The study was undertaken in accordance with the Declaration of
Helsinki and the European Medicines Agency Note for Guidance on
Good Clinical Practice. Patients provided written informed consent
before study procedures were initiated.
2.2 | Inclusion criteria
Obese patients (waist >88 cm in women and >92 cm in men; BMI
27-40 kg/m2) with type 2 diabetes, under treatment with lifestyle
changes or metformin (any dose), who had an HbA1c value of 42 to
75 mmol/mol (6%-9%) were eligible for the study. Additional inclusion
criteria were age of 30 to 75 years, triglycerides at 1.0 to 4.0 mmol/L
and LDL-cholesterol <4.5 mmol/L.
2.3 | Exclusion criteria
Exclusion criteria included type 1 diabetes, apoE2/2 phenotype, ele-
vated liver enzymes (alanine transaminase/aspartate transaminase
ratio > 3× upper limit of normal), eGFR <60 mL/min, clinically signifi-
cant thyroid-stimulating hormone outside normal range, use of lipid-
lowering drugs other than statins within 6 months, treatment with
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pioglitazone, insulin, sulphonylureas, gliptines, glinides, sodium-
glucose co-transporter 2 inhibitors or thiazide diuretics (at a dose of
>25 mg/day) within 6 months, uncontrolled blood pressure (>160 mm
Hg systolic and/or >105 mm Hg diastolic), history of pancreatitis,
stomach or other major bleeding, thyroid disorder, any medical condi-
tion that increases risk of dehydration, concurrent medical condition
that would interfere with interpretation of efficacy and safety data
during the study, absence of contraceptives in women of childbearing
potential, previous experience of side-effects from GLP-1 receptor
agonists, and non-compliance or withdrawn consent form.
2.4 | Randomization and study treatment
In total, 54 subjects were assessed for eligibility, of whom 31 were
excluded because of failure to meet inclusion criteria (n = 28) or
declining to participate (n = 1), or for other reasons (n = 2). All eligible
participants used stable daily doses of metformin and statin through-
out the study period. At screening, if a participant was not already
undergoing metformin and/or statin treatment, those treatments were
initiated. After a 4-week run-in period, participants were randomly
allocated (2:1) by the study physician to either the group receiving lir-
aglutide 1.8 mg or the group receiving placebo in a self-injecting
device for 16 weeks. Liraglutide and placebo were provided by Novo
Nordisk A/S. The study was single blinded, with two groups, in order
to achieve similar weight-loss in the liraglutide and placebo arms. The
groups were matched for age and BMI. Participants kept a 3-day food
diary before and at the end of the study treatment period. Participants
measured their weight at home and were supervised by a study nutri-
tionist (weekly contact) to achieve a weight loss goal of 3 kg. The
weight loss target was extrapolated from previous studies in popula-
tions with type 2 diabetes, being treated with background metformin,
that showed an average weight loss with liraglutide 1.8 mg of 2.8 to
3.4 kg.24–26 Participants were instructed to avoid alcohol and strenu-
ous exercise within 72 hours of each study visit. Serum amylase and
lipase were measured at screening, and at Weeks 8 and 16.
Participants attended the study centre on two separate occasions
before the treatment period for the fat-rich mixed meal tolerance test
and for abdominal magnetic resonance imaging. These tests were
repeated in participants after 14 to 16 weeks of treatment.
Participants' weight and height were measured in the study cen-
tre, barefoot with underwear, after an overnight fast. Waist circumfer-
ence was taken at the midpoint between the lower rib margin and the
iliac crest; three consecutive readings were taken, and the mean was
recorded. Body composition was assessed in a fasting state, after void-
ing, by a single-frequency bioelectrical impedance analysis (BIA) device
(Omron BF-500; Omron Medizintechnik, Mannheim, Germany).
2.5 | Fat-rich mixed meal test
Participants received a fat-rich mixed meal in the morning after an
overnight fast. The meal consisted of bread, butter, cheese, ham,
boiled eggs, fresh red pepper, low-fat (1%) milk, orange juice and tea
or coffee (56 g fat, 63 g carbohydrates and 40 g protein; total
927 kcal) and was consumed within 10 minutes. Blood samples were
obtained at fasting and at 0.5, 1, 2, 3, 4, 6 and 8 hours after the meal.
During the test, only water was allowed ad libitum and the partici-
pants remained physically inactive.
On the evening before the study day, participants received 2 g/
kg deuterated water (2H2O; Larodan Fine Chemicals, Solna, Sweden),
which was consumed between 6:00 PM and 10:00 PM to assess the
contribution of de novo lipogenesis to fatty acids in VLDL. A blood
sample was drawn as a background sample during the week before
the meal test day. De novo lipogenesis was analysed at 0 hour and
was calculated from enrichment of deuterated water ingested during
the kinetic study at the specified time points.12
2.6 | Proton magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy was performed using a
1.5-T whole-body device to determine liver fat content27 and subcu-
taneous abdominal and intra-abdominal fat.28 All analyses of imaging
results were performed by a single person (A. H.). Participants were
advised to fast for 4 hours before imaging.
2.7 | Biochemical analysis
Lipoprotein fractions (chylomicrons [Sf > 400]; large VLDL1 particles
[Sf 60-400] and smaller VLDL2 particles [Sf 20-60]) from blood samples
drawn before and during the fat-rich mixed meal test were separated
by density gradient ultracentrifugation.29 Triglyceride and cholesterol
concentrations in total plasma and lipoprotein fractions, as well as TRL
cholesterol and remnant-lipoprotein cholesterol, were analysed by auto-
mated enzymatic methods, using the Konelab 60i analyzer (Thermo
Fisher Scientific, Vantaa, Finland). Fasting and postprandial apolipopro-
tein (apo) B48 levels in total plasma were measured by ELISA
(Shibayagi, Shibukawa, Japan). Concentrations of plasma glucose and
insulin were measured using the hexokinase method (Gluco-quant;
Roche Diagnostic, Mannheim, Germany) and electrochemiluminescence
(Roche sandwich immunoassay on a Cobas autoanalyser), respectively.
Plasma levels of apoCIII were measured immunoturbidometrically
(Kamiya Biomedical Company, Seattle, Washington) and
β-hydroxybutyrate concentrations were measured by an enzymatic
method with a β-hydroxybutyrate FS kit (DiaSys Diagnostic Systems,
Holzheim, Germany) on a Konelab 60i analyzer (Thermo Fisher Scien-
tific). Plasma non-esterified fatty acids (NEFA) were analysed using an
automated enzymatic colorimetric method (Wako Chemicals, Neuss,
Germany).
2.8 | Statistical analysis
Statistical analyses were performed using SPSS (IBM Corporation,
New York, New York) and GraphPad Prism version 7 (http://www.
graphpad.com/scientific-software/prism/). Data are presented as
mean  SD or mean  SE. The area under the curve (AUC) was
calculated using the trapezoidal rule. For all variables, P values were
calculated using the Wilcoxon signed-rank test or the Mann–Whitney
U-test. Nonparametric tests were used, as many clinical variables
could not be assumed to be normally distributed. Correlation coeffi-
cients and their corresponding P values were calculated using
Spearman's rank test. Significance was set at P < 0.05.
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Matsuda Index and HOMA2-IR were calculated for time
points 0, 30, 60 and 120 minutes after the fat-rich mixed meal
test (for 63 g carbohydrates), using online-calculators (http://
mmatsuda.diabetes-smc.jp/4pointssi.html and http://www.dtu.ox.
ac.uk/homacalculator/).
Relative importance analysis, similar to partial R-squared analysis,
was undertaken to estimate how each of the measured variables con-
tributed to explaining the variance in the parameter of interest. If all
variables were uncorrelated, this quantification would be equivalent
to the variable's individual R-squared value. However, because this
was not the case, we calculated each variable's relative contribution
using four methods: lmg,30 pratt,31 last32 and first.32 The mean of
these four methods is presented as results. The analysis was per-
formed using the R package “relaimpo” (https://cran.r-project.org/
web/packages/relaimpo/relaimpo.pdf).32 Repeated measures ANOVA
was used to test for within-group differences before, compared to
after, the 16-week intervention for variables measured at several time
points after the oral fat tolerance test.
3 | RESULTS
3.1 | Demographics, body weight and glycaemia
We recruited 23 participants (17 men, 6 women) to the study. In total,
22 participants completed the study. One participant in the liraglutide
arm discontinued the study at Week 7 because of nausea. None of
the other participants reported adverse effects during the study, with
the exception of mild nausea. Table 1 presents the characteristics of
study participants.
Mean weight loss was similar in both groups at Week 16: −2.4 kg
(−2.5%) in the liraglutide group and −2.1 kg (−2.2%) in the placebo
group (Table 1). Regression analysis of weekly body weight measure-
ments showed significant time effects for the liraglutide group
(P = 1.2e-15) and the placebo group (P = 7.7e-6), but no significant
group effect (P = 0.10), indicating that participants in both groups lost
weight at a similar rate. Individual weight curves during the study are
available online (Figure S1, Supporting Information).
As expected, liraglutide treatment resulted in a significant lowering
of fasting glucose concentration and HbA1c, but no improvements in
glycaemic control were observed in the placebo group (Table 1). Fol-
lowing a fat-rich mixed meal, the postprandial responses of glucose and
insulin were attenuated in the liraglutide group (P < 0.05; one-way
repeated measures ANOVA for AUC) but not in the placebo group
(Figure 1 and Table S1, Supporting Information). Multiple regression
analysis showed a significant difference between the groups with
regard to reductions in HbA1c (P = 0.022), fasting glucose (P = 0.0030)
and glucose AUC (P = 0.0023) when controlling for weight loss.
3.2 | Fat depots, de novo lipogenesis and hepatic fat
oxidation
Liver fat decreased significantly in both groups, by 31% and 18% in
the liraglutide and placebo groups, respectively, after 16 weeks of
treatment (Table 1). Both visceral adipose tissue and subcutaneous
adipose tissue decreased significantly in the liraglutide group but not
in the placebo group (Table 1). We also estimated adipose tissue con-
tent using the bioimpedance analysis (BIA) method, and found it to be
in line with MRI results, with no variation or difference in loss of fat-
free mass (muscle) or in fat mass between the groups. Estimates of
loss of visceral fat mass showed a trend towards greater loss in the
LIRA group, but the difference was not significant (P = 0.069).
However, decreases in liver fat, visceral adipose tissue or subcu-
taneous adipose tissue did not differ significantly between the two
groups in a multiple regression analysis with weight change and group
included in the model as independent variables (data not shown).
We did not observe any significant changes in hepatic de novo
lipogenesis (Table 1), in fasting levels or postprandial β-hydroxybuty-
rate, a marker of hepatic fat oxidation, or in NEFA responses in either
group (Table 1, Figure 1 and Table S1).
3.3 | Fasting and postprandial lipids
Liraglutide treatment resulted in a trend towards reduction in fasting
triglycerides (P = 0.064) and significant reductions in fasting LDL-
cholesterol but did not induce any change in HDL-cholesterol
(Table 1). No changes in fasting lipids occurred in the placebo group
(Table 1). Despite similar weight loss in both groups, postprandial tri-
glyceride, chylomicron-triglyceride, VLDL1-triglyceride and apoB48
responses were attenuated only in the liraglutide group (P < 0.05;
one-way repeated measures ANOVA) (Figure 2 and Table S1, Sup-
porting Information). Furthermore, postprandial remnant-like particle
cholesterol (RLP)-cholesterol and TRL-cholesterol responses were sig-
nificantly decreased in the liraglutide group, but not in the placebo
group (P < 0.05; one-way repeated measures ANOVA) (Figure 3 and
Table S1, Supporting Information). Multiple regression analysis
showed a significant difference between the groups in changes in
postprandial AUC for triglycerides (P = 0.03) and chylomicron-
triglycerides (P = 0.0065), but not in changes in postprandial AUC for
VLDL1-triglycerides, apoB48, TRL-cholesterol or RLP-cholesterol
when controlling for weight loss.
We also studied the impact of liraglutide on apoCIII, a critical reg-
ulator of postprandial triglyceride metabolism33. Fasting apoCIII con-
centrations decreased markedly, by 10.7%, in the liraglutide group
(P = 0.018), but not in the placebo group (P = 0.578). Postprandial
apoCIII responses were also attenuated in the liraglutide group
(P < 0.001), but not in the placebo group (P = 0.25) (Figures 3 and S1,
Supporting Information).
3.4 | Determinants of metabolic improvements
Despite similar weight loss in both groups, the only significant
changes observed in the placebo group were reductions in liver fat
and systolic blood pressure (Table 1), whereas multiple metabolic
improvements were observed in the liraglutide group (see above). To
determine the factors that are driving the decrease in postprandial
TRL-cholesterol, RLP-cholesterol and apoCIII, we performed a correla-
tion analysis of changes in metabolic parameters during the treatment
period in the liraglutide group. We found that decreases in apoCIII
were significantly related to decreases in glucose (r = 0.65; P = 0.009)
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and HbA1c (r = 0.64; P = 0.01), but were not related to changes in
weight, liver fat, visceral adipose tissue or subcutaneous adipose tis-
sue (Figure S2, Supporting Information). Changes in apoCIII also corre-
lated significantly with decreases in postprandial AUC values for
plasma triglycerides, RLP-cholesterol and TRL-cholesterol (Figure S2,
Supporting Information). Thus, these results highlight the importance
of apoCIII as a link between glycaemic control and hypertriglyceridae-
mia and the importance of its role as a modulator of postprandial TRL
remnant metabolism.
We performed a relative importance analysis to determine the
impact of improvements in weight, liver fat, visceral fat and glycaemia
on postprandial triglyceride, TRL-cholesterol, RLP-cholesterol and
apoCIII responses. Approximately half of the variation in postprandial
triglyceride, TRL-cholesterol and RLP-cholesterol responses (48%,
56% and 59%, respectively) were explained by reductions in postpran-
dial apoCIII AUC alone (Figure 4A-C). In contrast, reductions in weight,
glycaemic control, postprandial insulin AUC or liver fat individually
explained less than 10% of the changes in these lipid-related variables
(Figure 4A-C). We also examined which variables would explain the
reduction in postprandial apoCIII AUC. Approximately 43% of the var-
iation in the reduction in postprandial apoCIII AUC was explained by a
reduction in HbA1c alone, with other factors explaining less than 7%
TABLE 1 Characteristics of study subjects (n = 22) at baseline and at Week 16
Liraglutide group Placebo group
Sex, men/women 13 / 2 3 / 4
Age, years 62  2 63  2
Duration of diabetes, years 7.8  4.7 5.9  6.5
Before After Change P Before After Change P
Weight, kg 98.6  11.0 96.1  11.2 −2.4  2.5
(−2.5%)
0.002 92.0  7.4 89.8  6.3 −2.1  3.0
(−2.2%)
0.128
BMI, kg/m2 31.8  3.4 31.0  3.7 −0.8  0.8
(−2.5%)
0.003 33.0  4.1 32.3  4.1 −0.7  1.2
(−2.2%)
0.128
Waist, cm 114.4  6.7 111.8  8.0 −2.6  3.6
(−2.3%)
0.017 115.0  5.5 112.4  6.2 −2.6  4.4
(−2.2%)
0.352
Syst. RR, mm Hg 135  14 139  11 4  13 (3.5%) 0.173 145  10 137  11 −8  6 (−5.2%) 0.018
Diast. RR, mm Hg 81  7 86  5 5  6 (6.7%) 0.012 86  6 85  8 −1  6 (−1.0%) 0.397
Heart rate, beats/
min
66  11 72  12 6  9 (10.4%) 0.014 63  13 65  9 2  12 (6.8%) 0.933
fP-Glucose, mmol/
L
8.3  2.4 6.4  1.2 −1.9  1.4
(−20.9%)
0.001 6.5  0.8 6.4  0.9 −0.0  0.3
(−0.8%)
0.865
HbA1c, mmol/mol 53.4  11.4 47.0  8.1 −6.4  7.4
(−10.9%)
0.005 45.0  3.8 46.0  5.6 1.0  3.1 (2.1%) 0.343
HbA1c, % 7.0  1.0 6.4  0.7 −0.6  0.7
(−7.8%)
0.005 6.3  0.3 6.4  0.5 0.1  0.3 (1.5%) 0.343
Insulin, μU/mL 13.9  4.8 14.5  4.9 0.6  3.9 (8.3%) 0.532 13.8  6.9 14.1  5.5 0.2  4.2 (19.6%) 0.735
Matsuda index 2.5  1.0 3.5  1.8 1.0  1.5 (45%) 0.017 3.1  1.7 3.1  1.3 0.01  0.9 (6.7%) 0.753
HOMA2-IR 2.0  0.7 2.0  0.6 0.0  0.5 (2.1%) 1 1.9  0.9 1.9  0.7 0.0  0.5 (19%) 0.81
Cholesterol, mmol/
L
4.0  0.7 3.8  0.7 −0.2  0.4
(−4.5%)
0.064 4.4  0.9 4.4  1.1 0.0  0.5 (−0.8%) 0.933
HDL-C, mmol/L 1.3  0.4 1.3  0.4 0.0  0.2 (2.8%) 0.950 1.5  0.3 1.5  0.3 0.0  0.1 (0.9%) 0.799
Triglycerides,
mmol/L
1.7  0.7 1.5  0.6 −0.2  0.6
(−10.8%)
0.064 1.4  0.6 1.3  0.4 −0.1  0.4
(−4.3%)
0.469
LDL-C, mmol/L 2.1  0.7 1.8  0.6 −0.2  0.3
(−10.2%)
0.008 2.5  0.9 2.3  0.8 −0.2  0.3
(−5.2%)
0.237
apoCIII, mg/dL 12.0  4.4 9.9  3.7 −2.1  3.4
(−10.7%)
0.018 9.7  2.8 8.6  1.8 −1.1  2.6
(−7.2%)
0.578
DNL, μmol/L 15.4  7.4 19.1  13.1 4.4  10.1 (35%) 0.152 12.6  7.5 13.8  11.2 1.2  6.6 (13.7%) 0.866
NEFA, μmol/L 541  134 504  179 −0.7  209
(−4.2%)
0.426 649  230 580  188 −69  262
(−4.5%)
0.688
β-OH, mg/dL 1.0  0.7 0.8  0.5 −0.2  0.5
(−13%)
0.188 1.6  1.2 1.0  0.8 −0.5  1.0
(−22%)
0.219
Liver fat, % 14.8  7.4 10.7  6.3 −4.1  2.9
(−31.0%)
0.001 16.1  9.3 13.9  9.7 −2.2  1.9
(−17.9%)
0.028
VAT, cm3 3403  941 3185  1014 −217  393
(−6.8%)
0.047 2710  836 2600  825 −110  249
(−4.2%)
0.499
SAT, cm3 4043  1129 3792  1185 −251  239
(−7.1%)
0.004 5400  1598 5161  1653 −239  345
(−4.9%)
0.128
Abbreviations: β-OH, β-hydroxybutyrate; DNL, de novo lipogenesis; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue. Data are given as
mean  SD. Mean changes from baseline to Week 16 are shown with SD and percentages. Within-group P values were calculated using the Wilcoxon
signed-rank test; P values < 0.05 are indicated in bold.
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individually (Figure 4D). We also used a regression model, in which
change in HbA1c was excluded in favour of change in fasting glucose.
In this model, reductions in fasting glucose explained 32% of the vari-
ation in reduction in postprandial apoCIII AUC.
4 | DISCUSSION
In the present study, we investigated how a 16-week treatment
period with the long-acting GLP-1 analogue liraglutide affected body
composition, ectopic fat depots, liver lipid handling and postprandial
TRL metabolism in patients with adequately controlled type 2 diabetes
who were undergoing statin and metformin treatment. Because lira-
glutide is known to promote weight loss, we compared liraglutide and
placebo in a study designed to achieve similar weight loss in both
groups. Weight reduction was similar in both groups and, as expected,
treatment with liraglutide improved glycaemia. We also observed that
treatment with liraglutide resulted in multiple improvements in cardio-
metabolic risk factors that were not seen in the placebo group. These
improvements appeared to be affected, in part, by weight-dependent
mechanisms and, in part, by liraglutide-specific effects.
FIGURE 1 Responses of plasma glucose, insulin, β-hydroxybutyrate and NEFA after a fat-rich mixed meal before treatment (open squares) and at
week 16 (filled squares) in patients with type 2 diabetes being treated with liraglutide (n = 15) or receiving placebo (n = 7). P values were
calculated using the ANOVA repeated measures test for within-group differences
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We observed that concentrations of serum triglycerides, chylomi-
crons and large VLDL1 particles after a high-fat mixed meal were sig-
nificantly lower at the end of the treatment period in the liraglutide
group, but not in the placebo group. These data indicate that liraglu-
tide treatment promoted more consistent reductions in postprandial
lipaemia than did placebo and suggest that the effect of liraglutide on
the postprandial chylomicron response may be, in part, independent
of weight loss. These results are in line with proposed class effects of
incretin-based therapies on postprandial TRL metabolism.34
Another novel finding was the marked reduction in postprandial
atherogenic remnant particles in the liraglutide group. Studies with
the dipeptidyl peptidase-IV inhibitors alogliptin35 or vildagliptin,36 or
with a single injection of the GLP-1 receptor agonist exenatide,37 have
shown beneficial effects on remnant cholesterol, but we are not
aware of previous results concerning RLPs after long-term treatment
with GLP-1 receptor agonists. We have reported previously a strong
correlation between RLP-cholesterol and increased VLDL1-
triglycerides in type 2 diabetes.6 Remnant cholesterol is directly linked
to the formation of atherosclerotic plaques, as the size and charge of
RLPs allow them to penetrate into and to be retained in the vascular
intima.38–40 Increased postprandial RLPs may be important, therefore,
for the accelerated atherogenesis in type 2 diabetes. Indeed, RLP-
cholesterol has been shown to independently predict prevalent coro-
nary artery disease.4,5,41 It can thus be hypothesized that the
FIGURE 2 Responses of plasma triglycerides (TG), chylomicron TG, VLDL1 TG and plasma apoB48 after a fat-rich mixed meal before treatment
(open squares) and at week 16 (filled squares) in subjects with type 2 diabetes treated with liraglutide (n = 15) or placebo (n = 7). P values were
calculated using the ANOVA repeated measures test for within-group differences
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improved metabolism of remnant particles induced by liraglutide may
lead to decreased intimal cholesterol deposition and CVD. However,
this remains to be tested in clinical outcome studies.
Postprandial concentrations of TRLs are regulated mainly by the
balance between production and clearance of these particles. The
amount of liver fat plays a critical role in this process and hepatic lipid
accumulation associates with the overproduction of large VLDL1 par-
ticles.42 The direct effect of liraglutide on liver fat has been studied
both in patients with type 2 diabetes and in non-diabetic control par-
ticipants.20 We observed significant decreases in liver fat in both the
liraglutide group (31%) and the placebo group (18%), but the differ-
ence between the groups was not significant, possibly because of the
small number of participants included in the placebo group. Genetic
variation can also affect the susceptibility for liver fat accumulation,
but there was no difference in the incidence of genetic variants,
PNPLA3, TM6SF2 or MBOAT7, linked to increased hepatic steatosis
between the groups (data not shown). Notably, we did not observe
any effects of liraglutide on hepatic β-oxidation, de novo lipogenesis
or postprandial NEFA concentrations. Thus, findings from earlier
in vitro studies, indicating that GLP-1 suppresses hepatic lipogenesis43
and activates hepatic fatty acid β-oxidation,44 could not be confirmed
in this clinical study.
A recent study in seven patients with non-alcoholic steatohepati-
tis (NASH) reported that treatment with liraglutide (1.8 mg daily)
induced minor reductions in hepatic de novo lipogenesis and NEFA
flux to the liver.45 However, participants in the liraglutide group lost
6 kg of body weight so the effects reported might be weight depen-
dent. Furthermore, the authors did not report whether any changes in
liver fat were noted for NASH patients. Notably, several studies have
failed to confirm the expression of GLP-1 receptors in hepatocytes,46
possible indicating that the primary sites of action of GLP-1 are non-
hepatic.
Which factors could explain the improvement in postprandial TRL
metabolism in response to liraglutide therapy? Previous studies have
shown that apoCIII concentrations closely correlate with plasma tri-
glyceride levels,40,47,48 and here we observed marked reductions in
fasting and postprandial apoCIII concentrations in the liraglutide
group. Furthermore, these reductions correlated closely with improve-
ments in glucose and HbA1c. Hepatic apoCIII expression is increased
by glucose through activation of the carbohydrate-responsive
FIGURE 3 Responses of plasma apoCIII, remnant-like particle cholesterol (RLP-C) and triglyceride-rich lipoprotein cholesterol (TRL-C) after a fat-
rich mixed meal before treatment (open squares) and at week 16 (filled squares) in subjects with type 2 diabetes treated with liraglutide (n = 15)
or placebo (n = 7). P values were calculated using the ANOVA repeated measures test for within-group differences
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element-binding protein (ChREBP)49. Therefore, apoCIII has been
identified as an important link between hyperglycaemia and hypertri-
glyceridaemia.33 We recently demonstrated that both apoCIII and
plasma triglycerides were markedly reduced by a carbohydrate-
restricted diet in obese patients with NAFLD.50 Consistently, the
decrease in postprandial apoCIII responses during liraglutide therapy
explained at least 50% of the reductions in postprandial triglycerides,
RLP-cholesterol and TRL-cholesterol. Interestingly, liver fat loss or
improvement in insulin sensitivity by Matsuda Index or HOMA2-IR
explained less than 10% of these parameters in the model. These
results are in line with earlier turn-over studies using stable isotopes
that have revealed that increased secretion of VLDL1-triglycerides
explains only a minor part of the increased serum triglycerides in
obese patients with NAFLD, and that the main determinant of plasma
triglycerides in these patients is impaired clearance of VLDL1-triglyc-
erides.49 Importantly, this defect was closely associated with
increased concentrations of apoCIII.40 Furthermore, our previous data
suggest that the capacity of the lipolytic pathway is a determinant of
both fasting and non-fasting triglyceride levels.11 In light of these find-
ings, taken together, improved glycaemia during liraglutide treatment
may play a key role in improving postprandial TRL remnant
metabolism.
Our study has several strengths. It is the first report to investigate
how liraglutide affects ectopic fat depots, hepatic lipogenesis and fat
oxidation, and postprandial lipid metabolism in addition to glycaemia.
Second, the study was designed to test whether the cardiometabolic
beneficial effects of liraglutide are mainly weight independent or
weight-loss dependent. Third, the study clarifies for the first time
results concerning remnant lipoprotein metabolism after long-term
treatment with GLP-1 receptor agonists. Our study also has several
weaknesses. An important limitation is the small number of partici-
pants in the placebo group because of the 2:1 allocation design, which
FIGURE 4 Relative importance analysis demonstrating the percentage contribution of changes in various metabolic parameters to reduction
(delta, Δ) in A, plasma TG area under the curve (AUC); B, plasma remnant-like particle cholesterol (RLP-C) AUC; C, triglyceride-rich lipoprotein
cholesterol (TRL-C); and D, plasma apoCIII AUC. Height of bar shows the absolute percentage contribution, calculated using an average of four
different methods (see the Material and Methods section). Variables to be included in the regression model were chosen based on hypothesized
physiological relevance to the trait of interest. Exclusion of Matsuda index in favour of HOMA2-IR did not significantly affect the results
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results in lack of statistical power. Another limitation is the trend
towards baseline differences between the groups. In addition, the
study requires validation and it is too early to translate the beneficial
data concerning cardiometabolic risk factors into clinical practice.
However, our results lay the groundwork for future studies focused
on the cardiometabolic benefits of GLP-1 analogues. These studies
must better define the patient group that will gain most from the
reduction in cardiometabolic risk factors.
In summary, the results show that liraglutide intervention was
associated with multiple improvements in cardiometabolic risk factors
that were not seen in the placebo group. These improvements
appeared to be impacted, in part, by weight-dependent mechanisms,
and in part by liraglutide-specific effects. Of particular importance
was a marked reduction in postprandial atherogenic remnant particles
in the liraglutide group. The underlying mechanism may be improved
glycaemic control, which leads to reduced expression of apoCIII, a key
regulator of hypertriglyceridaemia in hyperglycaemic patients.
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